Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone sensors and apps could revolutionize monitoring of rare muscle diseases

NCT ID NCT05798325

Knowledge-focused Sponsor: Institut de Myologie, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests whether digital tools like smartphone apps, wearable sensors, and home spirometers can reliably track symptoms of neuromuscular diseases. Researchers will compare data collected at home with in-clinic measurements from 40 participants aged 12–60. The goal is to develop better, less burdensome ways to monitor disease progression in clinical trials and daily life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could enable more accurate and less burdensome remote monitoring for neuromuscular disease patients, potentially improving clinical trial design and access to care.
What could go wrong
This is a small feasibility study (40 participants) focused on validating tools, not testing a treatment. The tools may not work for all patients or diseases, and results may not generalize.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jun 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 12 and 60 years * Patients with a genetically confirmed/molecular-proven neuromuscular or neurometabolic disease\* * Patients experiencing walking difficulties in the home and at high risk of limiting participation and walking outside of the home. * Written informed consent * Able to comply with all protocol requirements, including video recording * Affiliated to or beneficiary of a social security scheme (for France) Exclusion Criteria: * Patients with undefined diagnosis or any diagnosis other than neuromuscular or neurometabolic disease * Patient walking 10m in less than 10s * Guardianship/trusteeship * Pregnant or nursing women * Patients having relevant concomitant pathologies that, in the appreciation of the investigator could interfere with protocol compliance * Patients not being affiliated with local social security (for France)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuromuscular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuromuscular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuromuscular diseases

Contacts and locations

Locations

  • Association Institut de Myologie

    Paris, 75013, France

  • John Walton Muscular Dystrophy Research Centre

    Newcastle upon Tyne, NE1 3BZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.